- Home
- INVE vs CUE Comparison
INVE vs CUE Comparison
Compare INVE & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- CUE
- Stock Information
- Founded
- INVE 1990
- CUE 2014
- Country
- INVE United States
- CUE United States
- Employees
- INVE N/A
- CUE N/A
- Industry
- INVE Computer peripheral equipment
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- INVE Technology
- CUE Health Care
- Exchange
- INVE Nasdaq
- CUE Nasdaq
- Market Cap
- INVE 85.9M
- CUE 59.5M
- IPO Year
- INVE 1997
- CUE 2018
- Fundamental
- Price
- INVE $3.66
- CUE $0.72
- Analyst Decision
- INVE Strong Buy
- CUE Strong Buy
- Analyst Count
- INVE 2
- CUE 2
- Target Price
- INVE $5.50
- CUE $3.00
- AVG Volume (30 Days)
- INVE 37.8K
- CUE 132.0K
- Earning Date
- INVE 11-06-2025
- CUE 11-13-2025
- Dividend Yield
- INVE N/A
- CUE N/A
- EPS Growth
- INVE N/A
- CUE N/A
- EPS
- INVE 3.12
- CUE N/A
- Revenue
- INVE $23,538,000.00
- CUE $8,286,000.00
- Revenue This Year
- INVE N/A
- CUE N/A
- Revenue Next Year
- INVE $9.98
- CUE $13.27
- P/E Ratio
- INVE $1.19
- CUE N/A
- Revenue Growth
- INVE N/A
- CUE N/A
- 52 Week Low
- INVE $2.86
- CUE $0.45
- 52 Week High
- INVE $4.29
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- INVE 49.91
- CUE 34.73
- Support Level
- INVE $3.58
- CUE $0.77
- Resistance Level
- INVE $3.85
- CUE $0.78
- Average True Range (ATR)
- INVE 0.14
- CUE 0.03
- MACD
- INVE -0.02
- CUE -0.01
- Stochastic Oscillator
- INVE 25.00
- CUE 9.53
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.